Carboxypeptidase G2 (CPG2) Inhibitor

TargetMol
Product Code: TAR-T10678
Supplier: TargetMol
CodeSizePrice
TAR-T10678-1mg1mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-5mg5mg£238.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-10mg10mg£321.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-25mg25mg£497.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-50mg50mg£687.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-100mg100mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10678-500mg500mg£1,797.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Carboxypeptidase G2 (CPG2) Inhibitor is a new CPG2 Inhibitor with antitumor activity.
CAS:
192203-60-4
Formula:
C13H15NO6S
Molecular Weight:
313.32
Pathway:
Proteases/Proteasome
Purity:
0.98
SMILES:
COc1ccc(SC(=O)N[C@@H](CCC(O)=O)C(O)=O)cc1
Target:
Carboxypeptidase

References

1. Khan, Tariq H.; Eno-Amooquaye, Ebun A.; Searle, Frances et al. Novel Inhibitors of Carboxypeptidase G2 (CPG2): Potential Use in Antibody-Directed Enzyme Prodrug Therapy. Journal of Medicinal Chemistry (1999), 42(6), 951-956. 2. Friedlos F, Lehouritis P, Ogilvie L et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res. 2008 Jul 1;14(13):4259-66. 3. Schepelmann S, Ogilvie LM, Hedley D et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 2007 May 15;67(10):4949-55. 4. Schepelmann S, Hallenbeck P, Ogilvie LM et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 2005 Jun 15;65(12):5003-8.